Multiple Myeloma
Conditions
Brief summary
This study is an investigator-initiated clinical study to evaluate the safety and tolerability of melphalan hydrochloride for injection in patients with relapsed or relapsed refractory multiple myeloma. Using the 3 + 3 dose escalation principle, 3-6 subjects per dose were enrolled, depending on the dose limiting toxicity (DLT) observed in the first cycle of chemotherapy for each subject. After completing the 21-day assessment of the first cycle of chemotherapy, if there was no DLT, the study started for the next dose group.
Detailed description
The escalation method was as follows: 1 subject in each dose group was evaluated for safety by the investigator, and another 2 subjects were evaluated with the permission of the investigator: if none of them experienced DLT, they were escalated to the next dose group.If 1 subject experiences DLT, another 3 subjects will be enrolled in the same dose group.If DLT is not observed in 3 newly added subjects, the study of the next dose group can be started.Dose escalation was terminated if 2 or more DLTs were observed in 3 subjects enrolled in each dose group, or 1 or more DLTs were observed in 3 additional subjects per group.This dose was judged as intolerable dose, and dose escalation was stopped at the same time. The previous dose group was used as MTD. If only 3 patients were enrolled in the previous dose group, 3 more patients were required (the continued dose escalation should be less thanintolerable dose). DLT was continued to be observed to determine MTD. Dose escalation for the same subject was not permitted.If a subject dropped out during the DLT observation period due to non-DLT reasons or did not complete DLT observation according to the protocol, continued enrollment of subjects is required to meet the requirement of 3 or 6 subjects per dose. The administration method is as follows: Melphalan Hydrochloride for Injection 9 mg/m2, 18 mg/m2, 27 mg/m2 and 40 mg/m2 (if there is no DLT in this dose group when the dose is up to 40 mg/m2).The primary objective of this phase is to determine the optimal dose of melphalan hydrochloride for injection, up to 40 mg/m2.
Interventions
Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
Sponsors
CASI Pharmaceuticals, Inc.
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Four dose groups. Using the 3 + 3 dose escalation principle, 3-6 subjects per dose group, according to the dose limiting toxicity (DLT) observed in the first cycle of chemotherapy for each subject. After completing the 21-day assessment of the first cycle of chemotherapy, if there was no DLT, the study started for the next dose group.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old, male or female; 2. Relapsed or refractory multiple myeloma according to IMWG. There is no requirement for the number of previous treatment lines in this study 3. With any one of the following measurable indicators: serum protein electrophoresis (SPEP) ≥ 1 g/dL (10 g/L), if IgA, IgD, IgE or IgM multiple myeloma subjects, ≥ 0.5 g/dL (≥ 5 g/L); urine M protein ≥ 200 mg/24h; serum free light chain (FLC) ≥ 10 mg/dL and abnormal serum free light chain kappa/lambda ratio; 4. Life expectancy ≥ 6 months; 5. ECOG score ≤ 2; 6. ECG QT interval ≤ 470 ms; 7. Neutrophil ≥ 1.0\*10\^9/L, platelet ≥ 75\*10\^9/L (or 50 \*10\^9/L if plasma cell infiltration in bone marrow more than 50%); 8. Tbil ≤1.5 ULN，AST and ALT≤3.0 ULN （Gilbert syndrome except); 9. eGFR ≥ 45 ml/min or creatinine ≤ 2mg/dl 10. Understand the contents of this study and have signed the informed consent form.
Exclusion criteria
1. primary amyloidosis, MGUS, or smoldering multiple myeloma or plasma cell leukemia (according to the World Health Organization criteria: peripheral blood ≥ 5%) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin) ; 2. primary refractory disease (i.e., no at least MR response to any prior therapy); 3. combined clinically significant comorbidities (investigator judged); 4. the presence of active infection; 5. history of other malignant tumors (except multiple myeloma) within 3 years before signing the informed consent; 6. Pregnant or lactating women; 7. radiotherapy or other anti-myeloma treatment within 14 days before signing the informed consent;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicity (DLT) | one month | Hematological toxicity: Grade 4 thrombocytopenia OR Grade 4 neutropenia more than 7 days; Any non - hematological toxicity of grade 3 or above, except: 1) Grade 3 nausea / vomiting or diarrhea with duration less than 72 hours; 2) Grade 3 fatigue with duration less than one week; Grade 3 fever; Grade 4 infusion reaction; |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The overall response rate | one month | Hematological response CR + VGPR + PR +MR |
| TTP | 12 months | Time to progression |
| Progression-Free Survival (PFS) | 12 months | PFS is defined as the time from drug administration to progression or death, whichever occurs first |
| Overall Survival (OS) | 12 months | OS is defined as the time from drug administration to death. |
Countries
China
Contacts
Primary ContactYang Liu
Outcome results
None listed